# Kyverna (KYTX) — Overview

KYTX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/kytx

## Price

Last close $5.97 on Oct 15, 2026. 52-week range $5.69 – $11.25.

## Company profile

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $0.00 |
| Revenue (quarter) | $0.00 |
| Revenue growth (year over year) | 0.00% |
| Gross profit (trailing twelve months) | $0.00 |
| Gross margin | 0.00% |
| Net income (trailing twelve months) | $0.00 |
| Net income (quarter) | −$38.3M |
| Net income growth (year over year) | 8.94% |
| Net margin | 0.00% |
| Return on equity | -87.24% |
| EPS (trailing twelve months) | −$2.92 |
| Book value per share | $2.69 |
| P/E (trailing twelve months) | — |
| Price to book | 2.2 |
| Debt to assets | 24.69% |
| Payout ratio | 0.00% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### How do I buy stock in Kyverna (KYTX)?

KYTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).